CEO Eric E Poma purchased 25,000 shares at $2.00 on 2025-08-21; stock now at $1.56, down 96.2% from $40.56 high; cluster of 3 other insiders buying in past 14 days.
CEO Eric E Poma initiated a 25,000-share position at $2.00, acquiring his first holdings in Calidi Biotherapeutics. This purchase occurs within a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated accumulation by company leadership. The timing coincides with severe price deterioration—the stock trades at $1.56, down 96.2% from the 52-week high of $40.56 and down 82.2% over the past 30 days, indicating acute market distress. Against a backdrop of negative net income of $-5.7M and a market cap of only $5.3M, the cluster buy pattern and CEO's initiation of a direct stake warrant scrutiny of whether this reflects material information asymmetry or management's assessment of intrinsic value relative to distressed pricing.